Literature DB >> 16407694

Antihypertensive therapy and its effects on potassium homeostasis.

Domenic A Sica1.   

Abstract

The role of potassium in cardiovascular disease and the importance of preserving potassium balance have emerged as clinical hot points, particularly as they relate to cardioprotective and renoprotective therapies that secondarily promote potassium retention. Antihypertensive medications that most commonly influence serum potassium levels and/or total body potassium include beta blockers and potassium-wasting and potassium-sparing diuretics as well as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Uncertainty exists as to the best way to monitor potassium levels when any of these drug therapies are used, particularly in the setting of chronic kidney disease and/or heart failure. Guidelines for the monitoring of serum potassium levels in the setting of antihypertensive therapy are at best makeshift and often drawn from the know-how of the treating physician.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407694      PMCID: PMC8109601          DOI: 10.1111/j.1524-6175.2006.05139.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  31 in total

1.  Pseudohyperkalemia caused by fist clenching during phlebotomy.

Authors:  B R Don; A Sebastian; M Cheitlin; M Christiansen; M Schambelan
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

2.  Diltiazem enhances potassium disposal in subjects with end-stage renal disease.

Authors:  R Solomon; A Dubey
Journal:  Am J Kidney Dis       Date:  1992-05       Impact factor: 8.860

Review 3.  Control by drugs of renal potassium handling.

Authors:  H Velázquez; F S Wright
Journal:  Annu Rev Pharmacol Toxicol       Date:  1986       Impact factor: 13.820

4.  Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).

Authors: 
Journal:  Am J Cardiol       Date:  1996-10-15       Impact factor: 2.778

5.  Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.

Authors:  S C Textor; E L Bravo; F M Fouad; R C Tarazi
Journal:  Am J Med       Date:  1982-11       Impact factor: 4.965

6.  Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.

Authors:  H A Cooper; D L Dries; C E Davis; Y L Shen; M J Domanski
Journal:  Circulation       Date:  1999-09-21       Impact factor: 29.690

7.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

8.  Hypokalaemia and diuretics: an analysis of publications.

Authors:  D B Morgan; C Davidson
Journal:  Br Med J       Date:  1980-03-29

9.  Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial.

Authors:  S MacMahon; G Collins; P Rautaharju; J Cutler; J Neaton; R Prineas; R Crow; J Stamler
Journal:  Am J Cardiol       Date:  1989-01-15       Impact factor: 2.778

Review 10.  Importance of potassium in cardiovascular disease.

Authors:  D A Sica; A D Struthers; W C Cushman; M Wood; J S Banas; M Epstein
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 May-Jun       Impact factor: 3.738

View more
  6 in total

Review 1.  A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy.

Authors:  Sarah E McDowell; Sarah K Thomas; Jamie J Coleman; Jeffrey K Aronson; Robin E Ferner
Journal:  J R Soc Med       Date:  2013-03       Impact factor: 5.344

Review 2.  Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review.

Authors:  Sarah E McDowell; Robin E Ferner
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

Review 3.  A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass.

Authors:  Jaydeep Sinha; Stephen B Duffull; Hesham S Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

Review 4.  Drug-induced hyperkalemia.

Authors:  Chaker Ben Salem; Atef Badreddine; Neila Fathallah; Raoudha Slim; Houssem Hmouda
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

5.  Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors.

Authors:  Yuki Saito; Hiroyuki Yamamoto; Hideki Nakajima; Osamu Takahashi; Yasuhiro Komatsu
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

6.  Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial.

Authors:  Damian J Damian; Roseanne McNamee; Matthew Carr
Journal:  BMC Cardiovasc Disord       Date:  2016-10-04       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.